Structure Therapeutics Announces $300 Million Private Placement Equity Financing
September 29, 2023 07:32 ET
|
Structure Therapeutics Inc.
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents...
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
September 29, 2023 07:30 ET
|
Structure Therapeutics Inc.
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily...
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023 16:05 ET
|
Structure Therapeutics Inc.
Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of...
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
August 03, 2023 17:32 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
June 07, 2023 08:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023 16:30 ET
|
Structure Therapeutics Inc.
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 30, 2023 16:30 ET
|
Structure Therapeutics Inc.
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...
硕迪生物宣布完成经增发的首次公开募股包括承销商全面行使购买额外美国存托股票的选择权
February 07, 2023 16:00 ET
|
Structure Therapeutics Inc.
旧金山和上海, Feb. 08, 2023 (GLOBE NEWSWIRE) --...
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2023 16:00 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
硕迪生物宣布经增发的首次公开募股的定价
February 02, 2023 20:59 ET
|
Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司（纳斯达克股票代码：GPCR）是一家临床阶段的全球化生物制药公司，致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日，公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票（ADS），每股ADS代表三股普通股，公开发行价格为每股ADS...